摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4'-O-demethyl-4β-(4''-nitroanilino)-4-desoxypodophyllotoxin | 127882-73-9

中文名称
——
中文别名
——
英文名称
4'-O-demethyl-4β-(4''-nitroanilino)-4-desoxypodophyllotoxin
英文别名
GL-331;(5S,5aS,8aR,9R)-9-(4-hydroxy-3,5-dimethoxyphenyl)-5-(4-nitroanilino)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[5,6-f][1,3]benzodioxol-8-one
4'-O-demethyl-4β-(4''-nitroanilino)-4-desoxypodophyllotoxin化学式
CAS
127882-73-9
化学式
C27H24N2O9
mdl
——
分子量
520.496
InChiKey
DLROLUIVVKTFPW-LVEBQJTPSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    206-207 °C(Solv: ethyl acetate (141-78-6))
  • 沸点:
    751.5±60.0 °C(Predicted)
  • 密度:
    1.459±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    3.9
  • 重原子数:
    38
  • 可旋转键数:
    5
  • 环数:
    6.0
  • sp3杂化的碳原子比例:
    0.3
  • 拓扑面积:
    141
  • 氢给体数:
    2
  • 氢受体数:
    10

SDS

SDS:ce399b75b5438e0060d1517929694720
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Synthesis of succinic acid 12α-deoxoartemisinyl ester 4′-O-demethyl-4β-(4″-nitroanilino)-4-desoxypodophyllotoxin
    作者:Yonghong Yuan、Dongzhi Wei、Yanhua Lu、Yuling Dou
    DOI:10.1007/s10600-007-0185-z
    日期:2007.9
    The succinic acid 12α-deoxoartemisinyl ester 4′-O-demethyl-4-β-(4″-nitroanilino)-4-desoxypodophyllotoxin was synthesized for the first time.
    首次合成了琥珀酸12α-脱氧青蒿酯4′-O-去甲基-4-β-(4″-硝基苯胺基)-4-脱氧鬼臼毒素。
  • Identification of Novel 4′-O-Demethyl-epipodophyllotoxin Derivatives as Antitumor Agents Targeting Topoisomerase II
    作者:Wenli Xi、Hua Sun、Kenneth F. Bastow、Zhiyan Xiao、Kuo-Hsiung Lee
    DOI:10.3390/molecules27155029
    日期:——
    compounds (11, 18, 27 and 28) induced protein-linked DNA break (PLDB) levels higher than those of GL-331 (6) and 2, and are assumed to be topoisomerase II (topo II) poisons more potent than 6 and 2. Compound 28, a potent topo II poison highly effective against KBvin cells, was further evaluated with a panel of tumor cells and was most active against HepG2. This compound also exhibited apparent in vivo
    4'- O-去甲基表鬼臼毒素(DMEP)的C4变异是优化该类化合物抗肿瘤谱的有效方法。因此,合成了两个系列的新型 DMEP 衍生物,正如预期的那样,这些衍生物的抗肿瘤谱随不同的 C4 取代基而变化。值得注意的是,大多数化合物显示出对依托泊苷 (2) 抗性 KBvin 细胞的显着抑制作用。其中四种化合物(11、18、27和28) 诱导的蛋白质连接 DNA 断裂 (PLDB) 水平高于 GL-331 ( 6 ) 和2,并被认为是拓扑异构酶 II (topo II) 的毒性更强大于6和2. 化合物28是一种对 KBvin 细胞非常有效的强效拓扑 II 毒物,用一组肿瘤细胞进一步评估,对 HepG2 最有效。该化合物还在肝癌 22 (H22) 小鼠模型中表现出明显的体内抗肿瘤功效。结果表明,DMEP 的 C4 衍生是鉴定具有优化抗肿瘤谱的强效拓扑 II 抑制剂的可行方法。
  • Method of using a COX-2 inhibitor and a topoisomerase II inhibitor as a combination therapy in the treatment of neoplasia
    申请人:Pharmacia Corporation
    公开号:US20030225150A1
    公开(公告)日:2003-12-04
    The present invention provides compositions and methods to treat, prevent or inhibit a neoplasia or a neoplasia-related disorder in a mammal using a combination of a COX-2 inhibitor and a topoisomerase II inhibitor.
    本发明提供了使用 COX-2 抑制剂和拓扑异构酶 II 抑制剂组合治疗、预防或抑制哺乳动物肿瘤或肿瘤相关疾病的组合物和方法。
  • Method of using a cox-2 inhibitor and a topoisomerase II inhibitor as a combination therapy in the treatment of neoplasia
    申请人:Masferrer L Jaime
    公开号:US20060105961A1
    公开(公告)日:2006-05-18
    The present invention provides compositions and methods to treat, prevent or inhibit a neoplasia or a neoplasia-related disorder in a mammal using a combination of a COX-2 inhibitor and a topoisomerase II inhibitor.
    本发明提供了使用 COX-2 抑制剂和拓扑异构酶 II 抑制剂组合治疗、预防或抑制哺乳动物肿瘤或肿瘤相关疾病的组合物和方法。
  • Antitumor agents. 113. New 4.beta.-arylamino derivatives of 4'-O-demethylepipodophyllotoxin and related compounds as potent inhibitors of human DNA topoisomerase II
    作者:Zhe Qing Wang、Yao Haur Kuo、Dora Schnur、J. Phillip Bowen、Su Ying Liu、Fu Sheng Han、Jang Yang Chang、Yung Chi Cheng、Kuo Hsiung Lee
    DOI:10.1021/jm00171a050
    日期:1990.9
    A number of 4'-O-demethylepipodophyllotoxin derivatives possessing various 4 beta-N-, 4 beta-O- or 4 beta-S-aromatic rings have been synthesized and evaluated for their inhibitory activity against the human DNA topoisomerase II as well as for their activity in causing cellular protein-linked DNA breakage. The results indicated, that for DNA topoisomerase II, a basic unsubstituted 4 beta-anilino moiety is structurally required for the enhanced activity. Substitution on this moiety with CN, COOCH3, COOC2H5, OH and COOCH3, OCH3, COCH3, CH2OH, OCH2O, OCH2CH2O, phenoxy, morpholino, NO2, and NH2 either at the para and/or the meta position yielded compounds which are as potent or more potent than etoposide. Substitution with COOC2H5 and OH at the ortho position afforded inactive compounds. Replacement of the aryl nitrogen with oxygen or sulfur gave compounds which are much less active or inactive. However, replacement of the phenyl ring with a pyridine nucleus furnished compounds which are as active or slightly more active than etoposide. There is a lack of correlation between the ability of these compounds in inhibiting DNA topoisomerase II and in causing protein-linked DNA breaks.
查看更多

同类化合物

鬼臼脂毒酮 鬼臼毒素-4-O-葡萄糖苷 鬼臼毒素 鬼臼毒素 苦鬼臼毒素 脱氧鬼臼毒素 磷酸依托泊甙 盾叶鬼臼素 澳白木脂素2 澳白木脂素1 替尼泊苷 托尼依托泊苷 去氧鬼臼毒素 克立米星C 他氟泊苷 丙氨酸,N-(羧基甲基)-(9CI) alpha-盾叶鬼臼素 alpha-依托泊苷 [(5R,5aR,8aR,9R)-9-(4-羟基-3,5-二甲氧基-苯基)-8-氧代-5a,6,8a,9-四氢-5H-异苯并呋喃并[5,6-f][1,3]苯并二氧戊环-5-基]丁酸酯 TOP-53二盐酸盐 NK-611盐酸盐 5,8,8a,9-四氢-9-羟基-5-(3,4,5-三甲氧基苯基)-(5R,5aR,8aR,9S)-呋喃并[3',4':6,7]萘并[2,3-d]-1,3-二氧杂环戊烯-6(5aH)-酮 4’-去甲鬼臼毒素 4’-去甲基表鬼臼毒素-Β-D-葡萄糖甙 4-{[(5S,5aS,8aR,9R)-9-(4-羟基-3,5-二甲氧苯基)-8-羰基-5,5a,6,8,8a,9-六氢呋喃并[3',4':6,7]萘并[2,3-d][1,3]二噁唑-5-基]氨基甲酰}苯基乙酸酯 4,6-O-苄叉-Β-D-葡萄糖甙鬼臼毒素 4'-去甲基表鬼臼毒素 4'-O-脱甲基-4-((4'-(1'-苯甲基哌啶基))氨基)-4-脱氧鬼臼毒 4 ’-去甲去氧鬼臼毒素 3-羟基-4H-吡喃-4-酮 3-氨基-N-[(5S,5aS,8aR,9R)-9-(4-羟基-3,5-二甲氧苯基)-8-羰基-5,5a,6,8,8a,9-六氢呋喃并[3',4':6,7]萘并[2,3-d][1,3]二噁唑-5-基]苯酰胺 2’-O-没食子酰基金丝桃甙 2(3H)-硫代酰苯,3-乙基二氢-3-(1-甲基乙基)-(9CI) 2'-氯依托泊苷 1-羟基-17-氧杂五环[6.6.5.0~2,7~.0~9,14~.0~15,19~]十九碳-2,4,6,9,11,13-六烯-16,18-二酮(non-preferredname) (8aR,9S)-9-[[(2R)-7,8-二羟基-2-(2-噻吩基)-4,4a,6,7,8,8a-六氢吡喃并[5,6-d][1,3]二恶英-6-基]氧基]-5-(3,4,5-三甲氧基苯基)-5a,8,8a,9-四氢-5H-异苯并呋喃并[6,5-f][1,3]苯并二氧戊环-6-酮 (5S,5aS,8aR,9R)-5-[(4-氟苯基)氨基]-9-(4-羟基-3,5-二甲氧基-苯基)-5a,6,8a,9-四氢-5H-异苯并呋喃并[5,6-f][1,3]苯并二氧戊环-8-酮 (5S,5aR,8aR,9R)-9-(4-羟基-3,5-二甲氧基-苯基)-5-(4-羟基苯基)硫烷基-5a,6,8a,9-四氢-5H-异苯并呋喃并[5,6-f][1,3]苯并二噁唑-8-酮 (5R,5aR,8aS,9S)-9-[(4-氨基苯基)氨基]-5-(4-羟基-3,5-二甲氧苯基)-5,8,8a,9-四氢呋喃并[3',4':6,7]萘并[2,3-d][1,3]二噁唑-6(5aH)-酮盐酸(1:1) (5R,5aR,8aR,9R)-9-羟基-10-甲氧基-5-(3,4,5-三甲氧基苯基)-5a,8,8a,9-四氢-5H-异苯并呋喃并[6,5-f][1,3]苯并二氧戊环-6-酮 (5R,5aR,8aR,9R)-9-[[(6R,7R,8R)-7,8-二羟基-2-(4-甲氧基苯基)-4,4a,6,7,8,8a-六氢吡喃并[5,6-d][1,3]二恶英-6-基]氧基]-5-(3,4,5-三甲氧基苯基)-5a,8,8a,9-四氢-5H-异苯并呋喃并[6,5-F][1,3]苯并二氧戊环-6-酮 (5R,5aR,8aR,9R)-9-[[(6R,7R,8R)-7,8-二羟基-2-(2-羟基苯基)-4,4a,6,7,8,8a-六氢吡喃并[5,6-d][1,3]二恶英-6-基]氧基]-5-(3,4,5-三甲氧基苯基)-5a,8,8a,9-四氢-5H-异苯并呋喃并[6,5-F][1,3]苯并二氧戊环-6-酮 (5R,5aR,8aR,9R)-8-羰基-9-(3,4,5-三甲氧苯基)-5,5a,6,8,8a,9-六氢呋喃并[3',4':6,7]萘并[2,3-d][1,3]二噁唑-5-基乙酸酯 (5R,5aR,8aR,9R)-5-(4-乙氧基-3,5-二甲氧基-苯基)-9-[(2R,3R,4S,5S,6R)-3,4,5-三羟基-6-(羟基甲基)四氢吡喃-2-基]氧基-5a,8,8a,9-四氢-5H-异苯并呋喃并[6,5-f][1,3]苯并二氧戊环-6-酮 (5R,5aR,8aR,9R)-5-(3,5-二甲氧基-4-丙氧基-苯基)-9-[(2R,3R,4S,5S,6R)-3,4,5-三羟基-6-(羟基甲基)四氢吡喃-2-基]氧基-5a,8,8a,9-四氢-5H-异苯并呋喃并[6,5-f][1,3]苯并二氧戊环-6-酮 (5R)-5,8,8ab,9-四氢-5b-(3,4,5-三甲氧基苯基)呋喃并[3',4':6,7]萘并[2,3-d]-1,3-二氧杂环戊烯-6(5abH),9-二酮 (5-氯吡啶-3-基)丙酸甲酯 (3aS,4S,9R,9aR)-4-[(4-氟苯基)氨基]-9-(4-羟基-3,5-二甲氧基苯基)-6,7-二甲氧基-3a,4,9,9a-四氢-3H-萘并[3,2-c]呋喃-1-酮 (3aR,4S,9R,9aR)-4,6,7-三羟基-9-(4-羟基-3,5-二甲氧苯基)-3a,4,9,9a-四氢萘并[2,3-c]呋喃-1(3H)-酮 (1R,3aS,4R,6aR)-4-(1,3-苯并二氧戊环-4-基)-1-(1,3-苯并二氧戊环-5-基)-3,3a,4,6a-四氢-1H-呋喃并[3,4-c]呋喃-6-酮